Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Pharmaceuticals Inc., USA, (Glenmark) has launched Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA (axitinib) tablets. According to IQVIA sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA Tablets were around $538.4 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.